Study findings Sample Clauses

Study findings. Please provide a detailed description of your study’s findings.
Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs
Study findings. Both of the hypotheses presented in this study were supported. The first hypothesis asserted that there was a positive relationship between maintenance communication and democratic (i.e., joint) decision making. Supporting this hypothesis, a significant positive correlation was found between these two variables. The second hypothesis asserted that there was a positive relationship between democratic (i.e., joint) decision making and decision agreement. Once again, a significant positive correlation was found these two variables.
Sample 1Sample 2
Study findings. Office of the Undersecretary for Academic Affairs As- sessment Division. Evaluation and Planning Unit. Office of the Assistant Sec- retary for Academic Serv- ices. Office of the Associate Sec- retary for Special Edu- cation.
Sample 1
Study findings. First, the screener quantitative data was used to understand where screener survey participants access care in relation to where they live, their residence county locations and county locations of care were asked for within the screener survey and then both analyzed and visualized. This information is visualized on the next page in Figure 3.
Sample 1
Study findings. The survey was carried out in the 6 Project health facilities in Garissa, Embu and Kiambu Counties in December 2020. Garissa County is located in North Eastern region of Kenya comprising six sub- counties. It has a total population of 841,353 people with a total number of 126 health facilities. Embu County is in the former Eastern province of Kenya. Embu County serves a wider population in the Mt. Kenya region with a rising burden of cardiovascular disease. Embu county has a population of 608,599 people, of this 304,208 are male and 304,367 are female as per the 2019 national census data. Embu County has a population growth rate of 1.4% per annum. The county has 173 healthcare facilities comprising of private, non-governmental, faith based and public. Kiambu County is located in the central region of Kenya. The County covers a total area of 254.5km2 and has a total population of 2,417,735 as per the 2019 national census. The county has both private and public health facilities providing services to its population. The study facilities included one county referral hospital (level 5) and a selected sub-county hospital (level 4) in each county. In Garissa County, the Garissa Provincial General Hospital (GPGH) and Iftin Sub-county Hospital were included in the survey. Garissa PGH is a level five hospital located in Garissa town and has a 4-bed ICU and continuous monitoring of critical patients can be done in the ICU and HDU. Iftin level 4 hospital is a 24-bed hospital serving the Iftin sub-County in Garissa. In Embu County, Embu Level 5 hospital and Siakago level 4 hospital were included in the Project and the survey. Embu level 5 is a 618-bed hospital located in Embu town. The hospital has an ICU and HDU. Siakago (Mbeere) level 4 in Mbeere district with 42 bed facility with no ICU and HDU. It can have a turnover of 500 patients daily. In Kiambu County, Kiambu level 5 and Kihara level 5 facilities were included in the study. Kiambu level 5 is a 361-bed facility with a turnover of more than 2000 patients daily. The hospital has a recently established ICU. Kihara level 4 is an 84-bed facility located in Gachie Kiambu. The level 5 hospitals are better staffed with specialists, doctors, nurses and other cadres of staff.
Sample 1
Study findings. The analysis of qualitative data done generated several themes. The results are presented in six main themes which are:-first theme is the acceptability of Service Agreement as a tool toward strengthening PPP, which has two sub themes, namely: intention to renew the SA and benefits of implementing SA. The second theme deployment of Human Resources for Health to Cardinal Rugambwa Mission Hospital by the government, which has one sub-themes, namely number of HRH and the cadres of HRH deployed. The third theme is the government‟s financial commitment to support Cardinal Xxxxxxxx Mission Hospital. The fourth theme was on the provision of health services by the Cardinal Rugambwa Mission Hospital as per SA. The fifth theme is on the monitoring of the implementation of SA in Cardinal Rugambwa Mission Hospital by the government, which had six sub themes, namely Supportive supervision, Review meetings, spot checks, provision of guidelines, using submitted Annual plan, Monitoring of SA through HMT, CHSB and special committee. The sixth and last theme was on the factors affecting the implementation process of SA in Cardinal Rugambwa Mission Hospital which had six sub-themes, namely transportation, political factor, trust of one party to suppliers, trust between parties, presence of appointed PPP coordinator, and donor dependency.
Sample 1
Study findings. Having provided a critique of this study, and with the caveats about chance results in mind, it may be beneficial to provide a brief review of the study findings to inform future studies in this area. Overall, FHR at Time 1 appears to be useful in statistically predicting infant outcomes of alertness and self-regulation. On the other hand, trends were observed for FM and birth outcomes of gestational age and birth weight. None of the fetal responses were able to predict Xxxxx scores at 5 minutes. Within the limitations of the methods, small sample size, and unexpectedly healthy babies (e.g. optimal Xxxxx scores, gestational age, and birth weight) in this sample, the following conclusions can be drawn. Predicting Post-natal Outcomes
Sample 1
AutoNDA by SimpleDocs
Study findings. 9. The territorial and district-based parking supply and demand in base year and design years have been summarised and reviewed. Parking supply refers to the number of spaces available for parking and loading/unloading (L/UL), whereas parking demand refers to number of vehicles in need of a space for parking and L/UL during a specified time period. For night-time parking, the parking demand model shows that the supply to demand ratio of parking spaces was 0.75 in base year 2018 in territorial level for ComV. The ratio is estimated to drop in design years 2021, 2026 and 2031, with a ratio of 0.69 in 2031. For daytime L/UL in base year 2018, the model indicates that, the L/UL supply to demand ratio for GV was 1.03 while that of coaches/light buses was 0.33. The L/UL situation is expected to be more or less the same in design years 2021, 2026 and 2031.
Sample 1
Study findings 
Sample 1

Related to Study findings

  • Audit Findings Vendor shall implement any required safeguards as identified by Citizens or by any audit of Vendor’s privacy and security controls.

  • Findings 2. Based on the information known by or provided to the Department, the following findings are asserted for purposes of this Contract:

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Geotechnical Investigation Perform in accordance with the City Design Manual and other City requirements as designated in writing by the Director.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Claims Review Findings a. Narrative Results.‌‌

  • Office of Inspector General Investigative Findings Expert Review In accordance with Senate Bill 799, Acts 2021, 87th Leg., R.S., if Texas Government Code, Section 531.102(m-1)(2) is applicable to this Contract, Contractor affirms that it possesses the necessary occupational licenses and experience.

  • Protocols Each party hereby agrees that the inclusion of additional protocols may be required to make this Agreement specific. All such protocols shall be negotiated, determined and agreed upon by both parties hereto.

Time is Money Join Law Insider Premium to draft better contracts faster.